Search results
Found 10731 matches for
The new 7-year research collaboration with Janssen Research & Development, LLC (Janssen) will study patients at higher risk of developing certain types of blood cancers that arise from the immune system, such as chronic lymphocytic leukaemia and multiple myeloma, to identify markers that could be used to predict who will go on to develop symptomatic disease.
Matthew Jackson
DPhil, BSc (Hons) Matthew Jackson - Postdoctoral research scientist
Giulia Orlando
MSc, DPhil Giulia Orlando - Group Leader - Epigenetic Reprogramming in Cancer
Dimitris Vavoulis
BSc, MRes, MSc, PhD Dimitris Vavoulis - Computational Biologist
Rebecca Brehm
MSc Clinical Trials, BSc (Hons) Biological Sciences Rebecca Brehm - Clinical Trial Administrator - Oncology Clinical Trials Office (OCTO)
Sevasti Zervou
BSc(Hons) PhD FHEA Sevasti Zervou - Director of Studies, MSc Precision Cancer Medicine